1. Home

Target Audience

This activity is intended for community and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who care for patients with CLL.

Educational Objectives

Upon completion of this activity, participants should be able to:

• (YIM) Evaluate and interpret the clinical significance of emerging preclinical and clinical evidence regarding:
  • Factors contributing to the pathogenesis of CLL
  • The diagnosis, prognosis, and initial treatment of CLL
  • Contributors to disease progression and Richter’s transformation
• Assess the clinical trial results of current and emerging treatment strategies for patients with newly diagnosed CLL
• Evaluate the latest safety and efficacy data of approved and investigational approaches for patients with relapsed/refractory CLL
• Recognize best practices to achieve optimal outcomes among patients with CLL, including treating patients with high-risk disease, minimizing adverse events, and preventing progression of disease
• Review how the genomics, proteomics, and epigenetics of CLL play a role in the pathogenesis of disease
• Discuss optimal approaches to the identification and treatment of patients who develop Richter’s transformation
• Identify unique patient-related and disease-related factors that influence the care of patients with CLL, including vaccination, infection prevention, diet and exercise, and patient comorbidities
• Examine global perspectives and approaches for caring for patients with CLL, including access to care